Literature DB >> 18979624

Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution.

Stephan Schilling1, Claus Wasternack, Hans-Ulrich Demuth.   

Abstract

Several mammalian peptide hormones and proteins from plant and animal origin contain an N-terminal pyroglutamic acid (pGlu) residue. Frequently, the moiety is important in exerting biological function in either mediating interaction with receptors or stabilizing against N-terminal degradation. Glutaminyl cyclases (QCs) were isolated from different plants and animals catalyzing pGlu formation. The recent resolution of the 3D structures of Carica papaya and human QCs clearly supports different evolutionary origins of the proteins, which is also reflected by different enzymatic mechanisms. The broad substrate specificity is revealed by the heterogeneity of physiological substrates of plant and animal QCs, including cytokines, matrix proteins and pathogenesis-related proteins. Moreover, recent evidence also suggests human QC as a catalyst of pGlu formation at the N-terminus of amyloid peptides, which contribute to Alzheimer's disease. Obviously, owing to its biophysical properties, the function of pGlu in plant and animal proteins is very similar in terms of stabilizing or mediating protein and peptide structure. It is possible that the requirement for catalysis of pGlu formation under physiological conditions may have triggered separate evolution of QCs in plants and animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18979624     DOI: 10.1515/BC.2008.111

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  39 in total

Review 1.  Peptide toxins and small-molecule blockers of BK channels.

Authors:  Mu Yu; San-ling Liu; Pei-bei Sun; Hao Pan; Chang-lin Tian; Long-hua Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

2.  Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study.

Authors:  Philip Bender; Andreas Egger; Martin Westermann; Nadine Taudte; Anton Sculean; Jan Potempa; Burkhard Möller; Mirko Buchholz; Sigrun Eick
Journal:  Arch Oral Biol       Date:  2018-10-28       Impact factor: 2.633

3.  N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies.

Authors:  Y Diana Liu; Andrew M Goetze; Randal B Bass; Gregory C Flynn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

4.  Glutamine-specific N-terminal amidase, a component of the N-end rule pathway.

Authors:  Haiqing Wang; Konstantin I Piatkov; Christopher S Brower; Alexander Varshavsky
Journal:  Mol Cell       Date:  2009-06-26       Impact factor: 17.970

5.  Conodipine-P1-3, the First Phospholipases A2 Characterized from Injected Cone Snail Venom.

Authors:  Carolina Möller; W Clay Davis; Evan Clark; Anthony DeCaprio; Frank Marí
Journal:  Mol Cell Proteomics       Date:  2019-02-14       Impact factor: 5.911

6.  Cyclic peptides arising by evolutionary parallelism via asparaginyl-endopeptidase-mediated biosynthesis.

Authors:  Joshua S Mylne; Lai Yue Chan; Aurelie H Chanson; Norelle L Daly; Hanno Schaefer; Timothy L Bailey; Philip Nguyencong; Laura Cascales; David J Craik
Journal:  Plant Cell       Date:  2012-07-20       Impact factor: 11.277

7.  Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.

Authors:  Krysti Todd; Silvia Fossati; Jorge Ghiso; Agueda Rostagno
Journal:  Biochim Biophys Acta       Date:  2014-09-28

Review 8.  Factors affecting the physical stability (aggregation) of peptide therapeutics.

Authors:  Karolina L Zapadka; Frederik J Becher; A L Gomes Dos Santos; Sophie E Jackson
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

9.  Proteolytic systems of archaea: slicing, dicing, and mincing in the extreme.

Authors:  Julie A Maupin-Furlow
Journal:  Emerg Top Life Sci       Date:  2018-11-14

10.  [Alzheimer's disease. Molecular pathology, animal models, and current treatment].

Authors:  T A Bayer; O Wirths
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.